Acetic acids

FibroGen To Report First Quarter 2020 Financial Results

Retrieved on: 
Friday, April 24, 2020
Acetic acids, Isoquinolines, Roxadustat, Web.com, GlobeNewswire, NASDAQ, Economy of the United States, Finance, Companies

SAN FRANCISCO, April 24, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020.

Key Points: 
  • SAN FRANCISCO, April 24, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020.
  • ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
  • Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events .
  • The NDA filing for roxadustat for the treatment of CKD anemia was accepted by the U.S. Food and Drug Administration in February 2020.

FibroGen Reports UK Court Ruling

Retrieved on: 
Monday, April 20, 2020
Enzymes, Acetic acids, Transcription factors, Hypoxia-inducible factors, Roxadustat, HIF prolyl-hydroxylase inhibitor, Procollagen-proline dioxygenase, Hydroxylation, Astellas Pharma

SAN FRANCISCO, April 20, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdoms High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to be invalid.

Key Points: 
  • SAN FRANCISCO, April 20, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdoms High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to be invalid.
  • This decision does not affect the validity of these patents across the rest of Europe.
  • While FibroGen is disappointed with the courts decision, this UK ruling does not affect development or commercialization timelines for roxadustat, FibroGens HIF-PHI for treatment of anemia in chronic kidney disease, including in the UK or elsewhere in Europe.
  • Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.

LawnStar Makes EDTA Chelated Nutrients a Thing of the Past for Homeowners

Retrieved on: 
Thursday, April 16, 2020
Chemistry, Physical sciences, Natural sciences, Chelating agents, Amines, Acetic acids, Antidotes, Preservatives, Chelation, Ethylenediaminetetraacetic acid, Iron(III) phosphate, Soil

Yesterday, they announced the completion of a successful transition away from using EDTA and other traditional chelating agents, across their entire liquid plant nutrition line.

Key Points: 
  • Yesterday, they announced the completion of a successful transition away from using EDTA and other traditional chelating agents, across their entire liquid plant nutrition line.
  • Now, homeowners that value a lush lawn have a new alternative," said Luke Baldacchino, President.
  • LawnStarSugar Chelated Liquid Iron is stable up to 9.5pH, meaning it is suitable for even extreme levels of soil alkalinity.
  • About LawnStar:LawnStar manufactures easy-to-use liquid lawn care solutionsfocused on bringing consumers safer, greener, more reliable plant health products at afair price.

Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference

Retrieved on: 
Monday, March 23, 2020
Enzymes, Acetic acids, Pyridines, Vadadustat, Hypoxia-inducible factors, National Kidney Foundation, Procollagen-proline dioxygenase, NKF, HIF prolyl-hydroxylase inhibitor, Molidustat

CAMBRIDGE, Mass., March 23, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that the Company will present three posters at the upcoming National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference.

Key Points: 
  • CAMBRIDGE, Mass., March 23, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced that the Company will present three posters at the upcoming National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference.
  • The posters present studies of Akebia's investigational oral HIF-prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, which relates to Nobel Prize-winning science, the hypoxia-inducible factor (HIF) mechanism.
  • Akebia posters on vadadustat, to be presented at the NKF 2020 Spring Clinical Meetings Live Virtual Conference, are now available through the Abstract and ePoster Gallery and through the NKF SCM20 mobile app.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease.

Independent experts publish open letter challenging AAAS on failure to accept academic responses revealing key flaws in Science Magazine article supporting glyphosate ban in Europe and the United States

Retrieved on: 
Friday, February 14, 2020
Articles, Herbicides, Nature, Health, Monsanto, Acetic acids, Amines, Glyphosate, International Agency for Research on Cancer, Herbicide, United States Environmental Protection Agency, Carcinogen

MILANO, Italy, Feb. 14, 2020 /PRNewswire/ -- An Open Letter to AAAS Science Magazine from members of the SeTA (Science and Technology for Agriculture, www.setanet.it ) network.

Key Points: 
  • MILANO, Italy, Feb. 14, 2020 /PRNewswire/ -- An Open Letter to AAAS Science Magazine from members of the SeTA (Science and Technology for Agriculture, www.setanet.it ) network.
  • Consequently, they call for "natural and ecological weedkilling alternatives and less intensive farming practices."
  • Only IARC (2015) concluded that glyphosate is probably carcinogenic to humans while EPA warned against labelling glyphosate containing products as carcinogenic (EPA 2019).
  • NOTE: A shorter version of this letter was rejected by Science editor who did not provide us with an explanation.

Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Thursday, February 13, 2020
Research, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Enzymes, Procollagen-proline dioxygenase, Hypoxia-inducible factors, Acetic acids

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004 program at the 15th Annual Congress of the European Crohns and Colitis Organisation (ECCO) being held February 12- 15 in Vienna, Austria.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004 program at the 15th Annual Congress of the European Crohns and Colitis Organisation (ECCO) being held February 12- 15 in Vienna, Austria.
  • Details for the ECCO presentations are as follows:
    Poster Title: GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor, Induces HIF-1 Target Genes and is Efficacious in Mouse Colitis
    Poster Title: GB004, a Novel Gut-Targeted Prolyl Hydroxylase Inhibitor for Inflammatory Bowel Disease: First In-Human Multiple Dose Study in Healthy Subjects With Gut Biopsies
    Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology.
  • Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005151/en/

FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

Retrieved on: 
Tuesday, February 11, 2020
Enzymes, Chemical compounds, Branches of biology, Acetic acids, RTT, Isoquinolines, Roxadustat, Hypoxia-inducible factors, AstraZeneca, Procollagen-proline dioxygenase, Chronic kidney disease, Hydroxylation

The FDAs acceptance of the roxadustat new drug application is a critical step towards providing a new treatment option in the United States for chronic kidney disease patients suffering from anemia, a serious and often life-threatening disease, said Enrique Conterno, Chief Executive Officer, FibroGen.

Key Points: 
  • The FDAs acceptance of the roxadustat new drug application is a critical step towards providing a new treatment option in the United States for chronic kidney disease patients suffering from anemia, a serious and often life-threatening disease, said Enrique Conterno, Chief Executive Officer, FibroGen.
  • The filing of the roxadustat NDA triggers a $50 million milestone payment from AstraZeneca (LSE/STO/NYSE: AZN) to FibroGen.
  • Roxadustat is the first orally administered small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor accepted by the FDA for review for the treatment of anemia of CKD.
  • The NDA for roxadustat for treatment of CKD anemia was submitted to the U.S. FDA in December 2019.

FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference

Retrieved on: 
Tuesday, February 11, 2020
Telecommunications, Acetic acids, SVB Leerink, Roxadustat, Conterno, Webcast, Food and Drug Administration, Health

SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020.

Key Points: 
  • SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020.
  • Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at 3:30 PM Eastern Time.
  • A live audio webcast will be available on the Events & Presentations section of the FibroGen website at www.fibrogen.com.
  • The NDA for roxadustat for treatment of CKD anemia was submitted to the U.S. FDA in December 2019.

 Bayer Welcomes U.S. Environmental Protection Agency’s Reaffirmation that Glyphosate Is Safe to Use, Not Carcinogenic

Retrieved on: 
Friday, January 31, 2020
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Herbicides, Nature, Monsanto, Chemistry, Articles, Acetic acids, Amines, Glyphosate, Bayer, United States Environmental Protection Agency, Roundup, Monsanto legal cases

The EPA had already confirmed its position on glyphosate earlier this year.

Key Points: 
  • The EPA had already confirmed its position on glyphosate earlier this year.
  • EPA also reiterated its conclusion that glyphosate is not likely to be carcinogenic to humans, its most favorable rating.
  • Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world.
  • The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Global Agricultural Chelates Market Size is Estimated to be Valued at USD 0.9 Billion in 2019 & is Projected to reach USD 1.5 Billion by 2025, Recording a CAGR of 7.7% - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 16, 2020
Professional services, Consulting, Chemistry, Physical sciences, Natural sciences, Acetic acids, Amines, Chelating agents, Chelation, Coordination chemistry, Equilibrium chemistry, Pentetic acid, Vegetable, Ethylenediaminetetraacetic acid

Fruits and vegetables are projected to be the largest segment during the forecast period.

Key Points: 
  • Fruits and vegetables are projected to be the largest segment during the forecast period.
  • Fruits and vegetables accounted for the largest share in the agricultural chelates market in 2019.
  • On the basis of type, the agricultural chelates market is categorized as EDTA, EDDHA, DTPA, IDHA, and others.
  • Europe is estimated to account for the largest share in the agricultural chelates market.